» Articles » PMID: 39741314

Distinct Phenotypes in the Preeclamptic-like Mouse Model Induced by Adenovirus Carrying SFlt1 and Recombinant SFlt1 Protein

Overview
Journal Eur J Med Res
Publisher Biomed Central
Specialty General Medicine
Date 2024 Dec 31
PMID 39741314
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Preeclampsia (PE) is a pregnancy-specific, multisystemic disorder that affects 2-8% pregnancies worldwide and is a leading cause of maternal and perinatal mortality. At present, there is no cure for PE apart from delivery the placenta. Therefore, it is important and urgent to possess a suitable animal model to study the pathology and treatment of PE. When exogenous soluble fms-like tyrosine kinase-1 (sFlt-1) is administered, pregnant animals develop a PE-like phenotype. However, there is no report on the comparison between different methods of constructing PE mouse models using sFlt-1.

Methods: In this study, the adenovirus carrying sFlt-1(ADV-Flt-1) and recombinant murine sFlt-1 protein (RM Flt-1) are two different methods were used to induce and compare PE-like mouse models. Pregnancy outcomes were examined on E14.5 and E17.5.

Results: Our data showed that on E14.5, the adenovirus carrying sFlt-1 induced PE-like phenotype, whereas recombinant murine sFlt-1 protein not. On E17.5, both the two methods induced PE-like phenotype including hypertension, proteinuria, fetal growth restriction, placental and glomerular endotheliosis. Importantly, in the adenoviral-mediated sFlt-1 group, the circulating concentration of sFlt-1 were higher than in the recombinant sFlt-1 group, leading to earlier and more severe symptoms of PE. The ADV-Flt-1 group is easy to operate, quickly effective and efficient. The RM Flt-1 group is safer and more stable, with good repeatability, but slower to take effect.

Conclusions: We proposed that the adenoviral-mediated sFlt-1 model can better simulate early-onset and severe PE.

References
1.
McCarthy F, Drewlo S, English F, Kingdom J, Johns E, Kenny L . Evidence implicating peroxisome proliferator-activated receptor-γ in the pathogenesis of preeclampsia. Hypertension. 2011; 58(5):882-7. DOI: 10.1161/HYPERTENSIONAHA.111.179440. View

2.
Levine R, Maynard S, Qian C, Lim K, England L, Yu K . Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004; 350(7):672-83. DOI: 10.1056/NEJMoa031884. View

3.
Burke S, Zsengeller Z, Khankin E, Lo A, Rajakumar A, DuPont J . Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia. J Clin Invest. 2016; 126(7):2561-74. PMC: 4922717. DOI: 10.1172/JCI83918. View

4.
Davisson R, Hoffmann D, Butz G, Aldape G, Schlager G, Merrill D . Discovery of a spontaneous genetic mouse model of preeclampsia. Hypertension. 2002; 39(2 Pt 2):337-42. DOI: 10.1161/hy02t2.102904. View

5.
Dimitriadis E, Rolnik D, Zhou W, Estrada-Gutierrez G, Koga K, Francisco R . Pre-eclampsia. Nat Rev Dis Primers. 2023; 9(1):8. DOI: 10.1038/s41572-023-00417-6. View